Cognitive Processing Therapy (CPT) for Perinatal Posttraumatic Stress Disorder (PTSD)
1 other identifier
interventional
60
1 country
1
Brief Summary
Pregnant women with a primary diagnosis of posttraumatic stress disorder (PTSD) (PTSD Checklist for DSM-5 (PCL-5) score \> 33) will be randomized to receive conventional cognitive processing therapy (CPT) (60-min session once/week for 12 weeks) or massed CPT (mCPT) (an intensive schedule of 12 60-min sessions over 5 days, approximately 2-3 sessions per day) via telemedicine, for treatment of PTSD. The research aims will be three-fold: (1) Evaluate the relative efficacy and tolerability of CPT vs. mCPT for treatment of perinatal PTSD and depression; (2) Determine the effect of CPT upon maternal-infant attachment and interaction; (3) Collect pilot data of obstetric and neonatal outcomes among those receiving the two CPT delivery schedules.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jul 2025
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 24, 2025
CompletedStudy Start
First participant enrolled
July 1, 2025
CompletedFirst Posted
Study publicly available on registry
July 11, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2026
July 11, 2025
July 1, 2025
1.4 years
June 24, 2025
July 8, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5)
PTSD Checklist for DSM-5 (PCL-5) will be used to collect information on PTSD symptoms. The PCL-5 for DSM-5 is a 20-item self-report measure. Higher scores reflect greater PTSD severity. Scoring is based on how much the patient has been bothered by the symptoms on a scale from "0 = not at all" to "4 = extremely." PCL-5 total symptom severity scores range from 0 to 80 with higher scores indicating greater PTSD severity. PCL-5 Monthly will be collected at Visit 1, and the PCL-5 weekly will be collected at 1 week, 4 weeks, 8 weeks, 12 weeks, and 16 weeks following initiation of treatment in both groups.
Baseline, then at 1 week, 4 weeks, 8 weeks, 12 weeks, and 16 weeks following initiation of treatment in both the mCPT and traditional CPT groups
Secondary Outcomes (4)
Patient Health Questionnaire (PHQ-9)
Baseline, then at 1 week, 4 weeks, 8 weeks, 12 weeks, and 16 weeks following initiation of treatment in both the mCPT and traditional CPT groups
Prenatal Attachment Inventory (PAI)
Baseline
Maternal Attachment Inventory (MAI)
Once within 1-90 days following participant's delivery (i.e once within 3 months postpartum)
Infant CARE-Index (CARE-Index)
Once within 1-90 days following participant's delivery (i.e once within 3 months postpartum)
Study Arms (2)
Regular CPT
EXPERIMENTALStandard-model Cognitive Processing Therapy (CPT) - one 60-min session per week for 12 weeks total
mCPT
EXPERIMENTALMassed CPT - two 60-min sessions each day for 5 consecutive days (10 sessions total)
Interventions
Standard-model Cognitive Processing Therapy (CPT) - one 60-min session per week for 12 weeks total
Massed CPT - two 60-min sessions each day for 5 consecutive days (10 sessions total)
Eligibility Criteria
You may qualify if:
- Female, ages 18-46, Pregnant (\< 25 weeks), able to read and write in English, History of at least 1 criterion A trauma, Primary diagnosis of PTSD (confirmed by SCID), Psychotropic medications must be stable with no changes ≥ 2 weeks (≥ 6 weeks for fluoxetine), and no medication changes can be made during the course of therapy
You may not qualify if:
- Not currently pregnant, Diagnosis of bipolar disorder, psychotic disorders, Suicidal ideation with plan or intent, Substance use disorder, Regular benzodiazepine use (\> 4x weekly)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Texas at Austin, Dell Medical School, Department of Psychiatry
Austin, Texas, 78701, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Erin Richardson
University of Texas at Austin
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Advanced Practice Nurse
Study Record Dates
First Submitted
June 24, 2025
First Posted
July 11, 2025
Study Start
July 1, 2025
Primary Completion (Estimated)
December 1, 2026
Study Completion (Estimated)
December 1, 2026
Last Updated
July 11, 2025
Record last verified: 2025-07
Data Sharing
- IPD Sharing
- Will not share